244 related articles for article (PubMed ID: 31711843)
1. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of the LacdiNAc-glycosylated prostate-specific antigen assay for prostate cancer detection.
Yoneyama T; Tobisawa Y; Kaneko T; Kaya T; Hatakeyama S; Mori K; Sutoh Yoneyama M; Okubo T; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Ito A; Koie T; Suda Y; Gardiner RA; Ohyama C
Cancer Sci; 2019 Aug; 110(8):2573-2589. PubMed ID: 31145522
[TBL] [Abstract][Full Text] [Related]
3. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
[No Abstract] [Full Text] [Related]
4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
7. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
9. The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
Jagarlamudi KK; Zupan M; Kumer K; Fabjan T; Hlebič G; Eriksson S; Osredkar J; Smrkolj T
Prostate; 2019 Jun; 79(8):856-863. PubMed ID: 30889628
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
11. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
12. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
Chung JH; Yu J; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
J Korean Med Sci; 2020 Oct; 35(41):e342. PubMed ID: 33107227
[TBL] [Abstract][Full Text] [Related]
13. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
[TBL] [Abstract][Full Text] [Related]
14. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
Haga Y; Uemura M; Baba S; Inamura K; Takeuchi K; Nonomura N; Ueda K
Anal Chem; 2019 Feb; 91(3):2247-2254. PubMed ID: 30669833
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study.
Mearini L; Ferri C; Lazzeri M; Bini V; Nunzi E; Fiorini D; Costantini E; Manasse GC; Porena M
Urol Int; 2014; 93(2):135-45. PubMed ID: 24732975
[TBL] [Abstract][Full Text] [Related]
16. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
17. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
[TBL] [Abstract][Full Text] [Related]
18. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes.
MacAskill F; Lee SM; Eldred-Evans D; Wulaningsih W; Popert R; Wolfe K; Van Hemelrijck M; Rottenberg G; Liyanage SH; Acher P
Int Urol Nephrol; 2017 Aug; 49(8):1335-1342. PubMed ID: 28477301
[TBL] [Abstract][Full Text] [Related]
20. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
Nan LB; Yin XT; Gao JP
Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
